Cracking the Code: Phil Sharp and the Biotech Revolution

We are thrilled to invite you to a special private screening of the forthcoming documentary, Cracking the Code: Phil Sharp and the Biotech Revolution next month. The screening will take place at 4pm on Thursday, April 24, 2025 at the Li Ka Shing Learning and Knowledge Center – Berg Hall. Following the film will be a discussion with Howard Y. Chang, MD, PhD and director Bill Haney.
Hosted by: The Stanford RNA Medicine Program
Thursday, April 24, 2025 | 4pm-6pm
4:00pm – Discussion and reception to follow
Li Ka Shing Learning and Knowledge Center
291 Campus Drive, Stanford, CA 94305
We hope you will join us for this special advance screening. Kindly RSVP by April 21, 2025.
RSVP Here
Seats are limited. First come, first served.
About the film:
Narrated by Mark Ruffalo, Bill Haney’s Cracking the Code: Phil Sharp and the Biotech Revolution explores the life of Phil Sharp – a farm boy from humble beginnings in rural Kentucky who makes a Nobel prize-winning discovery that sparks the biotechnology industry and catalyzes the mRNA and RNAi revolutions, and drug discovery that helped 7 billion people in 2024 alone.
Watch the trailer here
About the speakers:
Howard Y. Chang, MD, PhD – Virginia and D. K. Ludwig Professor of Cancer Research, and Professor of Dermatology and Genetics at Stanford University; Investigator at the Howard Hughes Medical Institute and Senior Vice President, Global Research, and Chief Scientific Officer at Amgen. Dr. Chang is the winner of the Albany Prize, Lurie Prize in Biomedical Sciences, and NAS Award in Molecular Biology for discoveries of regulatory RNAs. He is an elected member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. He is a serial entrepreneur having founded five biotech companies.
Bill Haney – Bill Haney is a filmmaker, inventor, and entrepreneur. His most recent film projects include Cracking the Code: Phil Sharp and the Biotech Revolution, and Jim Allison: Breakthrough. He has started more than a dozen companies and is currently the Co-founder and CEO of Dragonfly Therapeutics, a clinical stage biotech focused on novel NK-cell based immune engagers, and Co-founder & Chairman of Skyhawk Therapeutics, a clinical stage biotech focused on small molecule RNA splicing modifiers. Bill is a graduate of Harvard College and served as a Fellow of Harvard’s Kennedy School.